Engage Bio Analysis: $125K Raised
What is Engage Bio?
Engage Bio develops Tethosomes, a non-viral DNA medicine platform built to deliver therapeutic DNA with proven LNP technology. The company says its proprietary Tethosome protein localizes DNA to the nucleus, increasing expression by over 100-fold and avoiding immune sensor detection. Its site describes the platform as potent, durable, redosable, and scalable, with expression lasting months to years from a single dose.
Location
San Carlos, California, United States
Employees
1-10
Founded
2021
Product Features & Capabilities
- Tethosomes, non-viral DNA delivery platform, highly potent (over 100x expression), non-immunogenic, redosable (months to years of expression), ready to scale (low manufacturing complexity).
How much Engage Bio raised
Seed - $125K
March 29, 2022Lead Investor: Y Combinator, WorldQuant Ventures, and 2 others.
Who are the founders of Engage Bio
WO
Will Olsen
CEO
Market Focus
Engage Bio primarily focuses on the biotechnology industry, specifically in the development of genetic therapies using a new class of non-viral DNA medicines known as Tethosomes.
Business Model
Revenue generated through partnerships and collaborations in gene therapy and oncology.
Investors
- Y Combinator
- WorldQuant Ventures
- Unpopular Ventures
- 1 other investor (not specified)
Competitors Overview
Engage Bio operates in the market of non-viral DNA delivery systems, specifically focusing on Tethosomes for enhancing genetic medicines. Its main competitors include:
-
Thermo Fisher Scientific: They offer a range of non-viral delivery systems, including the Invitrogen Vivofectamine, which is designed for efficient nucleic acid delivery. Their CTS Xenon Electroporation System is notable for its high cell viability and recovery rates, making it effective for hard-to-transfect cells. This technology is advantageous for applications in gene therapy and vaccine development.
-
GenScript: Known for its CRISPR non-viral CAR-T knock-in optimization kits, GenScript provides cGMP-quality non-viral DNA payloads and has a strong focus on gene editing solutions. Their services simplify the CRISPR-based gene editing process, which can be a significant advantage in the rapidly evolving field of genetic therapies.
-
Danaher: They offer various gene therapy solutions, including non-viral delivery methods that utilize lipid nanoparticles. Danaher's approach emphasizes the lack of immunogenicity and the ability to target specific cell types, which can be crucial for effective gene therapy.
-
Bio-Rad Laboratories: Bio-Rad provides a suite of transfection tools and kits, including electroporation methods that are highly efficient for gene delivery. Their products cater to a wide range of applications, from bacterial to animal cells, which enhances their versatility in the market.
-
Altogen Biosystems: They specialize in high-efficiency transfection reagents and tissue-targeted in vivo kits. Their optimized protocols for DNA and RNA delivery are designed for various cell lines, which can be a significant advantage for researchers looking for reliable transfection solutions.
These competitors each have unique technologies and advantages that may appeal to different segments of the genetic medicine market, highlighting the competitive landscape Engage Bio operates within.
See something that needs updating? Suggest edits to this profile.